Roflumilast (APTA 2217) is an orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3', 5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling.

Roflumilast Impurity E is the impurity of Roflumilast. Roflumilast acts as a selective and long-acting the enzyme PDE-4 inhibitor(IC50 value of 0.8 nM).

Roflumilast N-Oxide-d4 is a deuterated compound of Roflumilast N-Oxide. Roflumilast N-Oxide has a CAS number of 292135-78-5. Roflumilast N-oxide is a PDE type 4 inhibitor.

Roflumilast N-oxide is an inhibitor of PDE type 4.